目的：探讨18F-FDG和2-18F-乙酸盐联合显像在区分不同转移潜能的肝癌裸鼠模型中的意义。方法：以人肝癌细胞株HepG2和QGY7701为研究对象进行体外侵袭实验，判断细胞侵袭转移能力的大小。通过体外核素摄取实验观察两株肝癌细胞18F-FDG和2-18F-乙酸盐的摄取差异性，并建立皮下荷瘤模型进一步观察两种示踪剂的活体显像特征，绘制感兴趣区（ROI）并计算瘤/非瘤比值。结果：HepG2细胞体外侵袭能力大于QGY7701（P<0.05）。HepG2细胞的18F-FDG和2-18F-乙酸盐摄取率均高于QGY7701，其摄取差异有统计学意义（P<0.05）。两株细胞18F-FDG摄取率与侵袭能力呈正相关（r=0.657，P<0.05）。活体显像中HepG2肿瘤组织的18F-FDG和2-18F-乙酸盐的摄取值亦高于QGY7701，其中18F-FDG的摄取差异有统计学意义（P<0.05）。结论：18F-FDG摄取值能够反映肝癌细胞侵袭转移能力的大小；同时18F-FDG Micro-PET显像能够区分两种肝癌模型，提示18F-FDG显像有助于预测肝癌的不同侵袭转移潜能力。
Abstract
Objective: The aim of study was to evaluate whether the 18F-FDG and 18F-fluoroacetate(18F-FAC) could be used to distinguish the different metastatic potential of hepatocellular carcinoma(HCC) models. Methods: Human HCC cell lines HepG2 and QGY7701 were cultured and implanted into nude mice to create HCC models. In vitro cell invasion assay was performed to judge invasion ability. Uptakes of 18F-FDG, 18F-FAC in two cells were assessed by in vitro uptake assay. In vivo imaging of tumor-bearing mice were obtained by animal PET/CT after injection of each tracer. ROI(region of interest) was drawn over tumor and lung to calculate T/NT(tumor/non-tumor). Results: The invasion ability of HepG2 was much higher than QGY7701(P<0.05), and the uptake ratio of 18F-FDG and 18F-FAC in HepG2 was higher than that in QGY7701(P<0.05) in vitro uptake assay. The 18F-FDG uptake of cells correlated with invasion capability(r=0.657, P<0.05). Meanwhile, in Micro-PET/CT study, the uptake of 18F-FDG and 18F-FAC in HepG2 tumor was higher than that in QGY7701 tumor(P<0.05). Conclusion: High uptake of 18F-FDG reflects higher invasion ability of HCC cell. Meanwhile, there is differentiation between two HCC models in 18F-FDG Micro-PET imaging. It indicates that 18F-FDG PET imaging could help to predict metastasis ability of HCC.
关键词
肝肿瘤 /
氟脱氧葡萄糖F18 /
乙酸盐类 /
正电子发射断层显像术
Key words
Liver neoplasms /
Fluorodeoxyglucose F18 /
Acetates /
Positron-emission tomography
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2010, 37(3): 468-482.
[2]Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F]fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2): 144-156.
[3]Kim YK, Lee KW, Cho SY, et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients[J]. Liver Transpl, 2010, 16(6): 767-772.
[4]张锦明，田嘉禾，姚树林，等. FDG模块自动化合成2-18F-乙酸盐及其临床前研究[J]. 中华核医学杂志，2007，27（4）：215-217.
[5]Lindhe O, Sun A, Ulin J, et al. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology[J]. Eur J Nucl Med Mol Imaging, 2009, 36(9): 1453-1459.
[6]Matthies A, Ezziddin S, Ulrich EM, et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT[J]. Eur J Nucl Med Mol Imaging, 2004, 31(5): 797.
[7]Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging—in vivo evaluation of 18F-fluoroacetate versus 11C-acetate[J]. J Nucl Med， 2007, 48(3): 420-428.
[8]Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses[J]. J Nucl Med， 2003, 44(2): 213-221.
[9]Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma[J]. J Nucl Med， 2007, 8(6): 902-909.
